UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) General Counsel Jason Drew Smith sold 7,379 shares of the firm's stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares of the company's stock, valued at approximately $294,853.52. The trade was a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
UroGen Pharma Stock Performance
Shares of URGN stock traded down $0.23 during trading on Friday, reaching $10.72. The company had a trading volume of 231,947 shares, compared to its average volume of 309,246. The company has a market capitalization of $251.38 million, a PE ratio of -3.40 and a beta of 1.08. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm's 50 day simple moving average is $11.01 and its two-hundred day simple moving average is $12.55. UroGen Pharma Ltd. has a one year low of $9.78 and a one year high of $20.70.
UroGen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.29. The business had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same period in the prior year, the firm earned ($0.68) earnings per share. Sell-side analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of UroGen Pharma in the 2nd quarter worth approximately $719,000. Barclays PLC grew its position in UroGen Pharma by 409.3% in the third quarter. Barclays PLC now owns 59,778 shares of the company's stock valued at $759,000 after acquiring an additional 48,040 shares during the period. Wesbanco Bank Inc. acquired a new position in UroGen Pharma during the third quarter worth $945,000. JPMorgan Chase & Co. lifted its holdings in shares of UroGen Pharma by 263.1% during the third quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company's stock valued at $864,000 after acquiring an additional 49,318 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company's stock valued at $5,787,000 after purchasing an additional 34,248 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company's stock.
Analysts Set New Price Targets
Several research firms recently commented on URGN. D. Boral Capital restated a "buy" rating and set a $25.00 price target on shares of UroGen Pharma in a report on Thursday, January 23rd. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a "strong-buy" rating in a report on Monday, October 14th. Oppenheimer reaffirmed an "outperform" rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. Finally, HC Wainwright restated a "buy" rating and issued a $60.00 target price on shares of UroGen Pharma in a research note on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $43.70.
Get Our Latest Stock Report on URGN
UroGen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
Before you consider UroGen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UroGen Pharma wasn't on the list.
While UroGen Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
